What is the ROE (Return on Equity) of Crossject this year?
The ROE of Crossject this year is -4.82 undefined.
Crossject ROE 2024
Crossject ROE
-4.82
Ticker
ALCJ.PA
ISIN
FR0011716265
WKN
A1XEH4
In 2024, Crossject's return on equity (ROE) was -4.82, a 339.29% increase from the -1.1 ROE in the previous year.
Crossject Aktienanalyse
What does Crossject do?
Crossject SA is a company that specializes in the development and manufacturing of innovative drug delivery systems. The company was founded in 2006 by a team of professionals with the goal of changing the way medications are administered. Crossject's history began with the development of a unique drug delivery system called ZENEO. This system is based on a proprietary technology called "Needle Free Injection" that allows for needle-free and painless medication administration. The technology is safe, easy to use, and enables the administration of liquid medications and even solids in the form of suspensions. Crossject specializes in the application of this technology and develops products in various areas, including adrenaline for the treatment of life-threatening allergic reactions, methotrexate for the treatment of cancer, and anti-inflammatory medications for the treatment of asthma and COPD. The business model of Crossject is based on the development and commercialization of products based on the ZENEO technology. The company collaborates with a range of partners to bring its products to market, including pharmaceutical companies and other drug manufacturers. Crossject aims to sell its products worldwide and already has distribution partners in various countries around the world. Crossject is also committed to advancing the development of new products based on this technology. The company invests a significant portion of its revenue in research and development and works closely with academic institutions and other research facilities to improve its technology and products. Crossject's product offering includes a wide range of medications used for the treatment of various conditions. One example is the adrenaline injection system developed for the rapid and effective treatment of anaphylactic shocks that can occur as severe allergic reactions in people with food allergies, insect venom allergies, or drug allergies. The system does not require a needle and is therefore easy and safe to handle. Another example is the methotrexate injection for the treatment of cancer and autoimmune diseases such as rheumatoid arthritis and psoriasis. Crossject has also developed a range of products to combat asthma and chronic obstructive pulmonary disease (COPD). In 2019, the company received regulatory approval for its first commercial ZENEO product as an emergency treatment for migraines. This product is a fast-acting migraine therapy that is administered subcutaneously to quickly and effectively relieve pain and accompanying symptoms of migraines. In summary, Crossject is an innovative company specializing in the development and commercialization of drug delivery systems. The company utilizes a proprietary technology that allows for needle-free and painless medication administration and collaborates closely with partners to sell its products worldwide. Crossject continues to invest in research and development to bring new products based on its technology to market and establish itself as a leading company in its field. Crossject ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Crossject's Return on Equity (ROE)
Crossject's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Crossject's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Crossject's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Crossject’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Crossject stock
How has the Return on Equity (ROE) of Crossject developed compared to the previous year?
The ROE of Crossject has increased by 339.29% increased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Crossject?
A high ROE indicates that Crossject generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Crossject?
A low ROE can indicate that Crossject is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Crossject affect the company?
A change in ROE (Return on Equity) of Crossject can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Crossject?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Crossject?
Some factors that can influence Crossject's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Crossject pay?
Over the past 12 months, Crossject paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Crossject is expected to pay a dividend of 0 EUR.
What is the dividend yield of Crossject?
The current dividend yield of Crossject is .
When does Crossject pay dividends?
Crossject pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Crossject?
Crossject paid dividends every year for the past 0 years.
What is the dividend of Crossject?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Crossject located?
Crossject is assigned to the 'Health' sector.
Wann musste ich die Aktien von Crossject kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Crossject from 9/11/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/11/2024.
When did Crossject pay the last dividend?
The last dividend was paid out on 9/11/2024.
What was the dividend of Crossject in the year 2023?
In the year 2023, Crossject distributed 0 EUR as dividends.
In which currency does Crossject pay out the dividend?
The dividends of Crossject are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Crossject
Our stock analysis for Crossject Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Crossject Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
